ARTICLE | Finance

RX+DX gambit

Oncology play Ambit files for IPO: Aims for drug-diagnostic combo

November 15, 2010 8:00 AM UTC

Based on interim Phase II data, Ambit Biosciences Corp. has filed to raise up to $86.3 million in an IPO.

The company expects to complete enrollment in 1H11 of the pivotal Phase II trial for lead candidate quizartinib to treat relapsed or refractory acute myelogenous leukemia (AML) in patients with internal tandem duplication activating mutation for FLT3 (FLT3-ITD), with data following six months later...